Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

42P - Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS) - Composition of a Prognostic FCM-Score for Overall Survival

Date

15 Oct 2022

Session

Poster display session

Presenters

aida santaolalla

Citation

Annals of Oncology (2022) 33 (suppl_8): S1383-S1430. 10.1016/annonc/annonc1095

Authors

A. santaolalla1, U. Oelschlaegel2, J. Timms1, S. Winter2, P. Parker3, C.N. Harrison4, T.M. Westers5, A.A. van de Loosdrecht5, M. van Hemelrijck6, U. Platzbecker7, S. Kordasti8

Author affiliations

  • 1 KCL - King's College London, London/GB
  • 2 Department of Internal Medicine, University Hospital „Carl-Gustav-Carus“, TU Dresden/DE
  • 3 King's College London Guy's Hospital, London/GB
  • 4 Guy and St Thomas NHS Foundation Trust - Guy's Hospital, London/GB
  • 5 Amsterdam UMC, VU University Medical center, Cancer Center Amsterdam, Department of Hematology,, Amsterdam/NL
  • 6 King's College London - KCL, London/GB
  • 7 Universitätsklinikum Leipzig - Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie, Leipzig/DE
  • 8 School of Cancer and Pharmaceutical Sciences, King’s College, London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 42P

Background

Flow cytometry (FCM) is a co-criterion in Myelodysplastic Syndromes (MDS) diagnostics. The aims of the present study were (1) to develop a composite prognostic FCM-Score for OS in MDS ; (2) to asess whether a computational algorithm could improve the identification of aberrant expression and cell population frequencies and (3) to validate the accuracy of the prognostic FCM-Score for OS in MDS in an independent cohort.

Methods

FCM was performed in bone marrow (BM) of 399 patients cytomorphologically classified as MDS. Cell populations were identified. OS was assessed following univariate and multivariable Cox proportional hazards regression analysis using log-rank likelihood test to calculate FCM prognostic models. Kaplan Meier curves, and receiver operating characteristic curve (ROC) were used to test independent prognostic value of the models versus known diagnostic FCM-scores (Ogata-, FCSS-, iFS-score). T-REX pipeline was applied to check the feasibility of an unsupervised machine learning approach in identifying the FCM parameters. Validation of the prognostic score with best performance in an independent cohort of 110 MDS patients was performed.

Results

Prognostic FCM-scores were calculated based on the 9 FCM parameters with independent prognostic impact. FCM-scores, FCM-A: HR (95 %CI) 3.20 (2.15 - 4.48); FCM-B: 4.08 (2.54 - 6.55)), outperformed well known diagnostic scores (Ogata-score (2.00 (1.29 – 3.11))). FCM-scores allowed a better prognostic grading than IPSS-R (HR (95 %CI): 2.37 (1.61-3.49)). Kaplan Meier survival curves stratified by FCM-score A and B showed a highly significant overall survival benefit for patients with a low score (p<.0001) and FCM-A and FCM-B scores presented better discrimation capability than IPSS-R ((AUC): 0.69, and 0.71 vs. 0.62). T-REX pipeline was able to identify differences in expression of significant parameters between the low and high scoring patients. The validation of the OS prognostic score obtained presented good discrimination performance (c-stats 0.764; AUC 0.7463).

Conclusions

A promising novel prognostic score based on distinct FCM characteristics which could predict overall survival in MDS patients was presented.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.